Top

Published in:

01-08-2015 | REVIEW

Association of serum total osteocalcin with type 2 diabetes and intermediate metabolic phenotypes: systematic review and meta-analysis of observational evidence

Authors: Setor Kwadzo Kunutsor, Tanefa Antoinette Apekey, Jari Antero Laukkanen

Published in: European Journal of Epidemiology | Issue 8/2015

Abstract

Serum total osteocalcin, a marker of bone formation, may regulate glucose metabolism and influence the risk of developing adverse metabolic outcomes. We conducted a systematic review and meta-analysis of published observational evidence, to assess and quantify the associations of serum total osteocalcin with type 2 diabetes and intermediate metabolic phenotypes [e.g., metabolic syndrome (MetS)]. Relevant studies were identified in a literature search of MEDLINE, EMBASE, Web of Science, and reference lists of relevant studies to May 2015. Mean differences and risk estimates (odds ratios or relative risks) with 95 % CIs were aggregated using random-effects models. Fifty-two observational (38 cross-sectional, eight cohort, five case–control, and one both cross-sectional and cohort) studies with data on 46,998 non-overlapping participants were included. Baseline serum total osteocalcin levels were significantly lower in type 2 diabetes compared with non-type 2 diabetes and in MetS compared with non-MetS in pooled analysis of cross-sectional evidence. Pooled risk estimates (95 % CIs) for type 2 diabetes in a comparison of extreme fourths of total osteocalcin levels were 0.23 (95 % CI 0.12, 0.46) and 0.89 (95 % CI 0.78, 1.01) for cross-sectional and cohort studies respectively. The corresponding estimate was 0.39 (0.27, 0.56) for MetS from cross-sectional evidence. In both cross-sectional and cohort studies, a unit increase in serum total osteocalcin levels was associated with a significant mean increase in HOMA-B and mean reduction in HbA1c; with significant mean reductions in fasting plasma glucose levels, HOMA-IR, and body mass index in only cross-sectional studies. Available evidence—mainly from cross-sectional studies, supports inverse associations of serum total osteocalcin with risk of adverse metabolic outcomes. Large-scale prospective studies are needed to establish whether serum total osteocalcin may be useful in the prevention of adverse metabolic outcomes such as type 2 diabetes.

Available only for authorised users

Price PA. Gla-containing proteins of bone. Connect Tissue Res. 1989;21(1–4):51–7; discussion 7–60.CrossRefPubMed

Gerdhem P, Isaksson A, Akesson K, Obrant KJ. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int. 2005;16(12):1506–12. doi:10.1007/s00198-005-1877-5.CrossRefPubMed

Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130(3):456–69. doi:10.1016/j.cell.2007.05.047.PubMedCentralCrossRefPubMed

Hauschka PV, Lian JB, Cole DE, Gundberg CM. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev. 1989;69(3):990–1047.PubMed

Ferron M, McKee MD, Levine RL, Ducy P, Karsenty G. Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone. 2012;50(2):568–75. doi:10.1016/j.bone.2011.04.017.PubMedCentralCrossRefPubMed

Lerchbaum E, Schwetz V, Nauck M, Volzke H, Wallaschofski H, Hannemann A. Lower bone turnover markers in metabolic syndrome and diabetes: the population-based Study of Health in Pomerania. Nutr Metab Cardiovasc Dis. 2015;. doi:10.1016/j.numecd.2015.02.002.PubMed

Yeap BB, Alfonso H, Chubb SA, et al. Higher serum undercarboxylated osteocalcin and other bone turnover markers are associated with reduced diabetes risk and lower estradiol concentrations in older men. J Clin Endocrinol Metab. 2015;100(1):63–71. doi:10.1210/jc.2014-3019.CrossRefPubMed

Yeap BB, Chubb SA, Flicker L, et al. Reduced serum total osteocalcin is associated with metabolic syndrome in older men via waist circumference, hyperglycemia, and triglyceride levels. Eur J Endocrinol. 2010;163(2):265–72. doi:10.1530/EJE-10-0414.CrossRefPubMed

Liatis S, Sfikakis PP, Tsiakou A, et al. Baseline osteocalcin levels and incident diabetes in a 3-year prospective study of high-risk individuals. Diabetes Metab. 2014;40(3):198–203. doi:10.1016/j.diabet.2014.01.001.CrossRefPubMed

10.

Movahed A, Larijani B, Nabipour I, et al. Reduced serum osteocalcin concentrations are associated with type 2 diabetes mellitus and the metabolic syndrome components in postmenopausal women: the crosstalk between bone and energy metabolism. J Bone Miner Metab. 2012;30(6):683–91. doi:10.1007/s00774-012-0367-z.CrossRefPubMed

11.

Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology. J Am Med Assoc. 2000;283(15):2008–12. doi:10.1001/jama.283.15.2008.CrossRef

12.

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PloS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097.PubMedCentralCrossRefPubMed

13.

Wells GA, Shea B, O’Connell D, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2011. www.ohri.ca/programs/clinical_epidemiology/oxford.asp. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (Accessed 10 Mar 2015).

14.

van Dijk GM, Maneva M, Colpani V, et al. The association between vasomotor symptoms and metabolic health in peri- and post-menopausal women: a systematic review. Maturitas. 2015;80(2):140–7. doi:10.1016/j.maturitas.2014.11.016.CrossRefPubMed

15.

Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13. doi:10.1186/1471-2288-5-13.PubMedCentralCrossRefPubMed

16.

Chêne G, Thompson SG. Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am J Epidemiol. 1996;144(6):610–21.CrossRefPubMed

17.

Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol. 1992;135(11):1301–9.PubMed

18.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. doi:10.1016/0197-2456(86)90046-2.CrossRefPubMed

19.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. doi:10.1136/bmj.327.7414.557.PubMedCentralCrossRefPubMed

20.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.PubMedCentralCrossRefPubMed

21.

Garnero P, Grimaux M, Demiaux B, Preaudat C, Seguin P, Delmas PD. Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. J Bone Miner Res. 1992;7(12):1389–98. doi:10.1002/jbmr.5650071206.CrossRefPubMed

22.

Szulc P, Varennes A, Delmas PD, Goudable J, Chapurlat R. Men with metabolic syndrome have lower bone mineral density but lower fracture risk—the MINOS study. J Bone Miner Res. 2010;25(6):1446–54. doi:10.1002/jbmr.13.CrossRefPubMed

23.

Kanazawa I, Yamaguchi T, Tada Y, Yamauchi M, Yano S, Sugimoto T. Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes. Bone. 2011;48(4):720–5. doi:10.1016/j.bone.2010.12.020.CrossRefPubMed

24.

Confavreux CB, Levine RL, Karsenty G. A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol Cell Endocrinol. 2009;310(1–2):21–9. doi:10.1016/j.mce.2009.04.004.PubMedCentralCrossRefPubMed

25.

Hinoi E, Gao N, Jung DY, et al. The sympathetic tone mediates leptin’s inhibition of insulin secretion by modulating osteocalcin bioactivity. J Cell Biol. 2008;183(7):1235–42. doi:10.1083/jcb.200809113.PubMedCentralCrossRefPubMed

26.

Ducy P. The role of osteocalcin in the endocrine cross-talk between bone remodelling and energy metabolism. Diabetologia. 2011;54(6):1291–7. doi:10.1007/s00125-011-2155-z.CrossRefPubMed

27.

Wei J, Karsenty G. An overview of the metabolic functions of osteocalcin. Curr Osteoporos Rep. 2015;. doi:10.1007/s11914-015-0267-y.PubMed

28.

Lee NK, Karsenty G. Reciprocal regulation of bone and energy metabolism. Trends Endocrinol Metab. 2008;19(5):161–6. doi:10.1016/j.tem.2008.02.006.CrossRefPubMed

29.

Hwang YC, Jeong IK, Ahn KJ, Chung HY. The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced beta-cell function in middle-aged male subjects. Diabetes Metab Res Rev. 2009;25(8):768–72. doi:10.1002/dmrr.1045.CrossRefPubMed

30.

Shea MK, Gundberg CM, Meigs JB, et al. Gamma-carboxylation of osteocalcin and insulin resistance in older men and women. Am J Clin Nutr. 2009;90(5):1230–5. doi:10.3945/ajcn.2009.28151.PubMedCentralCrossRefPubMed

31.

Kanazawa I, Yamaguchi T, Yamauchi M, et al. Adiponectin is associated with changes in bone markers during glycemic control in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009;94(8):3031–7. doi:10.1210/jc.2008-2187.CrossRefPubMed

32.

Kanazawa I, Yamaguchi T, Yamauchi M, et al. Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int. 2011;22(1):187–94. doi:10.1007/s00198-010-1184-7.CrossRefPubMed

33.

Takahashi M, Kushida K, Nagano A, Inoue T. Comparison of the analytical and clinical performance characteristics of an N-MID versus an intact osteocalcin immunoradiometric assay. Clin Chim Acta. 2000;294(1–2):67–76.CrossRefPubMed

34.

Gundberg CM, Nieman SD, Abrams S, Rosen H. Vitamin K status and bone health: an analysis of methods for determination of undercarboxylated osteocalcin. J Clin Endocrinol Metab. 1998;83(9):3258–66. doi:10.1210/jcem.83.9.5126.PubMed

35.

Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011. www.cochrane-handbook.org (Accessed 01 Mar 2013).

Title: Association of serum total osteocalcin with type 2 diabetes and intermediate metabolic phenotypes: systematic review and meta-analysis of observational evidence
Authors: Setor Kwadzo Kunutsor
Tanefa Antoinette Apekey
Jari Antero Laukkanen
Publication date: 01-08-2015
Publisher: Springer Netherlands
Published in: European Journal of Epidemiology / Issue 8/2015
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI: https://doi.org/10.1007/s10654-015-0058-x

At a glance: The STEP trials

Springer Medicine

Association of serum total osteocalcin with type 2 diabetes and intermediate metabolic phenotypes: systematic review and meta-analysis of observational evidence

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2015

Low mortality in the poorest areas of Spain: adults residing in provinces with lower per capita income have the lowest mortality

Healthy Living: The European Congress of Epidemiology, 2015

Income inequality, life expectancy and cause-specific mortality in 43 European countries, 1987–2008: a fixed effects study

The income inequality hypothesis rejected?

A Swiss paradox? Higher income inequality of municipalities is associated with lower mortality in Switzerland

Secular trends and educational differences in the incidence of type 2 diabetes in Finland, 1972–2007